Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection |
| |
| Institution: | 1. Department of Dermatology, Beijing Hospital, China;2. Department of Obstetrics and Gynecology, Beijing Hospital, China;1. Univ. Lille, Inserm, CHU Lille, U1189 – ONCO-THAI – Image Assisted Laser Therapy for Oncology, F-59000 Lille, France;2. Department of Gynecology, University of Lille, 59000 Lille, France;1. Univ. Lille, Inserm, CHU Lille, U1189 – ONCO-THAI – Image Assisted Laser Therapy for Oncology, F-59000 Lille, France;1. Univ. Lille, Inserm, CHU Lille, U1189 – ONCO-THAI – Image Assisted Laser Therapy for Oncology, F-59000 Lille, France;1. Univ. Lille, Inserm, CHU Lille, U1189 – ONCO-THAI – Image Assisted Laser Therapy for Oncology, F-59000 Lille, France;2. Department of Gynecology, University of Lille, 59000 Lille, France;1. Federal State Institution of Additional Vocational Training “Teaching and Research Medical Center” Office of the President of the Russian Federation, 121359, Marshal Timoshenko St., 21, Moscow, Russia;2. City Clinical Hospital No. 51 Moscow Health Department, 121309, Alyabiev St., 7/33, Moscow, Russia;3. Maimonides State Classical Academy, 115035, Sadovnicheskaya St., 52/45, Moscow, Russia;4. A.M Prokhorov General Physics Institute of Russian Academy of Sciences, 119991, Vavilov St.,38, Moscow, Russia;5. National Research Nuclear University (Moscow Engineering Physics Institute) MEPhI, 115409, Kashirskoe highway 31, Moscow, Russia;1. Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany;2. Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany;3. Clinic for Gynecology, Charité-Universitätsmedizin, Berlin, Germany;1. Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany;2. Clinic for Gynecology, Obstetrics, and Gynecological Oncology, Clinic of the City of Wolfsburg, Wolfsburg, Germany;3. Center of Excellence in Women’s Health, University of Arizona, Tucson, AZ;4. Center of Outpatient Gynecology Clinic and Primary Care, Brno, Czech Republic;5. private practice, Bratislava, Slovak Republic;6. Institute of Clinical Medicine, University of Bergen and Women’s Clinic, Haukeland University Hospital, Bergen, Norway;7. Department of Obstetrics and Gynecology and Women’s Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY;1. Department of Dermatology, Huadong Hospital, Fudan University, Shanghai, PR China;2. Department of Dermatology and Venereology, Shanghai Skin Diseases Hospital, Shanghai, PR China;3. University of Colorado Cancer Center, Denver, CO, USA;4. MOE Key Laboratory of OptoElectronic Science and Technology for Medicine, Fujian Normal University, Fuzhou, PR China |
| |
| Abstract: | ObjectiveTo investigate the clinical efficacy of 5-aminolevulinic acid photodynamic therapy (ALA–PDT) for cervical high-risk HPV (HR-HPV) infection.MethodsIn this prospective study, a total of 76 patients with persistent cervical HR-HPV infection were randomly divided into two groups. The treatment group (39 patients) received three treatments of ALA–PDT at two-week intervals. The control group (37 patients) received no treatment. All patients were followed up for 9 months. Hybrid Capture HPV DNA Assay and ThinPrep cytology test (TCT) were performed for both groups. Patients with abnormal TCT results received colposcopic biopsy before treatment and during follow-ups.ResultsHR-HPV remission rates were 64.10% (25/39) in the treatment group and 24.32% (9/37) in the control group at 3 month follow-up. Complete remission rates were 76.92% (30/39) and 32.40% (12/37), respectively, in the two groups at 9 month follow-up. There was a statistically significant difference between the two groups (P < 0.01). Conversion rates of abnormal TCT results were 81.81% (9/11) in the treatment group and 12.50% (1/8) in the control group at 3 months, and 90.90% (10/11) and 25.00% (2/8), respectively, at 9 months. Five of six patients with CIN I in the treatment group and no patients in the control group achieved complete response at 9 months. There was a statistically significant difference between the two groups (P < 0.01).ConclusionTopical ALA–PDT is an effective, safe and well tolerated treatment for cervical HR-HPV infection. |
| |
| Keywords: | 5-aminolevulinic acid High-risk human papillomavirus (HR-HPV) |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
